PPARA and type 2 diabetes mellitus: Another antidiabetic drug elafibranor (GFT505), a dual PPARα/δ agonist, can improve NASH and multiple cardiometabolic risk factors associated with metabolic syndrome and T2DM without worsening fibrosis at a dose of 120 mg/d for one year [22].